AOD9604 (Fragment 176-191): reported timelines in the literature

AOD9604 (Fragment 176-191) is a synthetic peptide corresponding to the C-terminal region of human growth hormone, residues 176 through 191. It is also referred to in the literature as AOD-9604 and as Anti-Obesity Drug 9604, and it is classed among the unapproved peptide compounds marketed directly to patients rather than among the agents that have completed a regulatory approval process [1][2]. The evidence block supplied for this page does not give a sequence string, a molecular formula or a molecular weight for the fragment, so none are stated here. The work reviewed centres on the growth hormone receptor and on the lipolytic and metabolic signalling attributed to the 176-191 region of the hormone.

Timelines are the question this page addresses, and the honest answer from the available evidence is that the literature does not supply a clean, human, time-resolved dataset for AOD9604. What exists is a body of preclinical work, largely animal and in vitro, plus review-level commentary that places the compound in the broader category of unapproved peptides used in sports medicine contexts [1][2][3]. Where a timeline is reported, it is reported in a specific model, and it does not transfer to other models or to humans. The sections below separate what was measured, in what system, and over what interval.

Research Studies

AOD9604 and the growth hormone receptor fragment region

The 176-191 fragment sits at the C-terminus of the growth hormone molecule, a region that has been examined separately from the full-length hormone because the metabolic and lipolytic activities attributed to growth hormone have been localised, in part, to this stretch of residues. The mechanistic framing in the review literature is that the fragment interacts with growth hormone receptor signalling while being studied independently of the anabolic and insulin-related actions associated with the intact hormone [1][2]. This is a mechanistic proposition about a receptor family, not a clinical finding, and the evidence block does not contain a receptor-binding affinity value, a dissociation constant or a dose-response curve for the fragment. Any statement about how tightly or how selectively the fragment engages the receptor would require data the evidence block does not provide, and is therefore omitted.

AOD9604 and lipolytic endpoints in animal models

The lipolytic activity of the 176-191 region is the endpoint most often associated with the fragment in preclinical discussion. In animal models, the reported readouts are changes in fat mass, lipolysis in adipose tissue preparations, and related metabolic markers. The evidence block does not supply the numerical results of those experiments, the species used, the doses administered, or the observation windows, so this page cannot report a timeline in days or weeks for any animal model. What can be said is that the animal work exists as a category, that it is preclinical, and that it does not by itself establish a timeline that applies to humans [1][2].

AOD9604 and in vitro adipose tissue preparations

In vitro work on the fragment uses adipose tissue or adipocyte preparations and measures lipolytic output directly. This is the setting in which a timeline is shortest and most tightly defined, because the readout is measured over the hours of an experiment rather than over the weeks of an animal study. The evidence block does not give the specific incubation intervals, the concentrations tested, or the magnitude of the response, so no in vitro timeline is quoted here. The distinction that matters for a reader is categorical: an in vitro lipolysis result is a laboratory observation in a prepared system, and it is not a timeline for an organism [1][2].

AOD9604 and the absence of a reported human timeline

The review material supplied describes AOD9604 as an unapproved compound marketed directly to patients, and it places the compound within a broader discussion of peptides whose safety and efficacy have not been established through the approval process [1][2][3]. That framing is the key timeline fact on this page: the literature reviewed does not report a human timeline for the fragment, because the human evidence base described is not one of completed efficacy trials. A reader looking for a number of weeks to an effect will not find one in this evidence, and inventing one would misrepresent the state of the record.

AOD9604 and regulatory status as a timeline variable

Regulatory status shapes what timelines can exist at all. Approved peptide drugs have passed through a process that evaluates safety and efficacy, and the studies generated during that process produce the longitudinal data that timelines are built from. Unapproved compounds marketed direct to patients, including AOD9604, have not generated that body of data, which is why the timeline literature for them is thin and why the review authors treat the two categories separately [1][2][3]. This is a statement about the evidence base, not about the compound's pharmacology.

AOD9604 and the sports medicine context

The review evidence situates peptide use, including unapproved peptides, within sports medicine, where demand for accelerated injury recovery and performance enhancement drives patient-directed marketing [1][2][3]. AOD9604 appears in that discussion as one of the named unapproved compounds. The evidence block does not report musculoskeletal outcomes, recovery intervals or performance measures for the fragment specifically, so no timeline for injury recovery or athletic performance is stated here. The context is reported; the endpoint data are not.

AOD9604 and comparison with approved peptide agents

Because the review evidence contrasts approved and unapproved peptides, a comparison table is useful for showing where the timeline evidence sits. The table below reports only what the evidence block supports: the category each compound belongs to and whether a human timeline is reported in the supplied material. It does not compare efficacy, because the evidence block does not provide efficacy values for either category.

AOD9604 and the limits of the supplied evidence

The evidence block for this page consists of review-level material on approved and unapproved peptide therapies in sports medicine [1][2][3]. It names AOD9604, gives its expansion as Anti-Obesity Drug 9604, and places it in the unapproved category. It does not contain primary pharmacokinetic data, primary animal study results, primary in vitro results, or any human trial data for the fragment. Every timeline statement that could be made from this evidence is therefore a statement about what is absent from the record, and that absence is the finding this page reports.

If you are reading this for personal health reasons

This material is sold for laboratory research use only, and we do not provide dosing, administration or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician rather than relying on a research catalogue page. Nothing here is a recommendation, a protocol or a promise of any outcome.

Sources

• [1] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v3
• [2] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v1
• [3] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://pubmed.ncbi.nlm.nih.gov/41966639/